<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123872</url>
  </required_header>
  <id_info>
    <org_study_id>20-2091-101</org_study_id>
    <nct_id>NCT05123872</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation as Home Treatment in Depression</brief_title>
  <acronym>GSUND_DAHOAM</acronym>
  <official_title>GleichStrom UND Depression: Anwendung zu Hause Ohne Anreise Zur Medbo (Transcranial Direct Current Stimulation and Depression: Home Treatment)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>neurocare group AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this one-armed study the feasibility and effectiveness of a home treatment with&#xD;
      transcranial direct currect stimulation in depression will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this one-armed study at least 10 patients with depression will be included who will get&#xD;
      treatment with transcranial direct currect stimulation at home. One visit in the hospital&#xD;
      before and one visit after the treatment are necessary. The correct application of the device&#xD;
      by the patients will be ensured by video counseling and monitoring. Treatment will last six&#xD;
      weeks with 2 mA applied every working day for 20min with prefrontal montage.&#xD;
&#xD;
      Aim of the study is the evaluation of the feasibility of this home treatment (usability of&#xD;
      the device, compliance of patients, usability of the video contacts), the effectiveness&#xD;
      (clinical ratings) and the tolerability of this treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Usability for the patients</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rating of the usability of the treatment (home treatment and video monitoring) with the user experience questionnaire [1-7, 26 items, the higher the better] and open feedback</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Usability for the handlers/clinicians</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rating of the usability of the treatment (home treatment and video monitoring) with the user experience questionnaire [1-7, 26 items, the higher the better] and open feedback</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance 1</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of days out of 30 the patients used the device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance 2</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of patients who completed the treatment regulary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficiancy 1</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of responders according the the clinical global impression change score for patients in the per protocol analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficiancy 2</measure>
    <time_frame>6 weeks</time_frame>
    <description>Effect size for change of depressivity for patients in the per protocol analysis measured with the Hamilton depression rating scale (21 items)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stability of effects 1</measure>
    <time_frame>18 weeks</time_frame>
    <description>Number of responders according the the clinical global impression change score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stability of effects 2</measure>
    <time_frame>18 weeks</time_frame>
    <description>Eeffect size for change of depressivity for patients in the per protocol analysis measured with the Hamilton depression rating scale (21 items)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton depression rating scale</measure>
    <time_frame>18 weeks</time_frame>
    <description>Depression rating scale (0-65, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory</measure>
    <time_frame>18 weeks</time_frame>
    <description>Depression inventory (0-50, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Quality of life scale (abbreviated Version) (WHOQOL-BREF)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Quality of life scale inventory (4-20, the higher the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clincial Global Impression change</measure>
    <time_frame>18 weeks</time_frame>
    <description>Clincial Global Impression (1-7, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh sleep quality index</measure>
    <time_frame>18 weeks</time_frame>
    <description>sleep inventory (0-21, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression anxiety stress scale (DASS)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Depression, anxiety and stress inventory (each 0-21, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personality styles and disorder inventory</measure>
    <time_frame>18 weeks</time_frame>
    <description>Depedence of treatment effect from personality as measured with the Personality styles and disorder inventory (PSDI) (T-value norms, values around 50 are normal)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>prefrontal tDCS at home</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side</description>
    <arm_group_label>prefrontal tDCS at home</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  depressive episode according to ICD-10&#xD;
&#xD;
          -  moderate depression according to clinical impression or Hamilton depression rating&#xD;
             scale&#xD;
&#xD;
          -  gender: all sexes&#xD;
&#xD;
          -  age: 18-70 years&#xD;
&#xD;
          -  stable medication if possible&#xD;
&#xD;
          -  no or stable treatment of depression&#xD;
&#xD;
          -  residence in Germany and mother language German&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications for transcranial direct current stimulation&#xD;
&#xD;
          -  neurological conditions&#xD;
&#xD;
          -  participiation in another study&#xD;
&#xD;
          -  pregnancy and lactation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berthold Langguth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Schecklmann, PhD</last_name>
    <phone>+49-941-941-2054</phone>
    <email>martin.schecklmann@medbo.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrike Stadler</last_name>
    <phone>+49-941-941-1256</phone>
    <email>tms-psy-r@medbo.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berthold Langguth</last_name>
      <phone>+49-941-941-2099</phone>
      <email>berthold.langguth@medbo.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Berthold Langguth, MD, Ph.D.</investigator_full_name>
    <investigator_title>Clinical Professor, MD, Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

